Rosalind Advisors Inc. Buys Shares of 125,000 uniQure N.V. $QURE

Rosalind Advisors Inc. bought a new stake in uniQure N.V. (NASDAQ:QURE) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 125,000 shares of the biotechnology company’s stock, valued at approximately $7,296,000. uniQure accounts for approximately 2.6% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 18th largest position.

A number of other hedge funds have also made changes to their positions in the stock. Private Trust Co. NA purchased a new position in uniQure during the third quarter valued at approximately $28,000. Jones Financial Companies Lllp lifted its position in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 5,538 shares during the period. Knott David M Jr acquired a new stake in shares of uniQure during the 3rd quarter valued at $117,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of uniQure during the 2nd quarter valued at $151,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at uniQure

In other news, insider Jeannette Potts sold 3,412 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the sale, the insider directly owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. This trade represents a 2.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jack Kaye sold 6,390 shares of uniQure stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares in the company, valued at $557,575.92. The trade was a 23.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 81,399 shares of company stock valued at $1,527,645. 4.79% of the stock is owned by corporate insiders.

uniQure Stock Performance

QURE opened at $16.94 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 10.43 and a current ratio of 10.43. The company has a market cap of $1.06 billion, a PE ratio of -4.91 and a beta of 0.73. The stock has a 50-day moving average of $21.53 and a 200-day moving average of $29.49. uniQure N.V. has a 52-week low of $7.76 and a 52-week high of $71.50.

uniQure (NASDAQ:QURE) last posted its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.93) by $0.37. The firm had revenue of $5.57 million during the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. As a group, equities research analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on QURE shares. Sanford C. Bernstein downgraded shares of uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of uniQure in a research report on Tuesday. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Finally, Stifel Nicolaus set a $14.00 price target on uniQure in a research note on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $43.25.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Mizuho upgraded uniQure to “outperform” with a $35 price target (up from $12), and multiple firms (RBC, Wells Fargo, Chardan) issued bullish commentary or upgrades this week, supporting short-term buying interest. Mizuho upgrade / coverage roundup
• Positive Sentiment: Royal Bank of Canada and Wells Fargo raised ratings on QURE (coverage noted by AmericanBankingNews), which helped earlier session rallies and increased analyst attention ahead of key drug catalysts. RBC upgrade article
• Neutral Sentiment: Seeking Alpha published an analysis titled “A Unique Situation For UniQure” that dissects catalysts and risks; the piece may influence investors weighing upside vs. regulatory/legal risk but does not present new primary facts. A Unique Situation For UniQure
• Negative Sentiment: Hagens Berman highlighted reports that the FDA publicly rebuked uniQure, alleging the company pushed “distorted” and “manipulated” data for the AMT-130 program — a serious regulatory credibility issue that increases the risk of further clinical/regulatory setbacks and fuels investor concern. Hagens Berman / FDA accusation alert
• Negative Sentiment: Multiple plaintiff law firms (Pomerantz, Bernstein Liebhard, Faruqi, Levi & Korsinsky, Rosen, Kahn Swick & Foti, ClaimsFiler) have filed or solicited investors in securities class actions and are publicizing April lead-plaintiff deadlines — raising potential litigation liability and ongoing headline risk. Pomerantz class action alert Bernstein Liebhard shareholder alert
• Negative Sentiment: HC Wainwright cut near- and multi-year earnings forecasts substantially (Q1–Q4 2026 and FY2026–FY2030 revisions), which signals weaker expected near-term financials and reduces forward EPS visibility despite the firm’s “Buy” rating — a factor pressuring valuation. HC Wainwright estimate revisions (MarketBeat summary)

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.